STAT3 and cholangiocarcinoma: For CCA treatment, several non-peptide SH2 domain or STAT3 inhibitors have been identified, including STA-21, IL-6, STTT, TIC, C188-9, OPB-31121/51602, WP1066, S3I-201, BP-1-102, STX-0119, and HJC0123 (see [105] and the references therein), although the efficacy of these agents requires further confirmation.